• Sulfo-Cy3 NHS Ester: Evidence, Scope and Limits

  2026-10-06

  A source-grounded overview of Sulfo-Cy3 NHS Ester, the principles behind amine-reactive fluorescent labeling, and what a recent collateral-circulation study does—and does not—show about interpreting fluorescence in vascular biology.

• Chloroquine in Cancer Therapy: Review Findings

  2026-10-05

  The 2024 review by Liu and colleagues examines how Chloroquine may influence cancer biology through both autophagy-dependent and autophagy-independent mechanisms. Its main contribution is a broad pharmacological synthesis linking lysosomal effects, cell-death pathways, combination therapy, toxicity, and translational limitations rather than treating autophagy inhibition as a complete explanation.

• Chloroquine Diphosphate in Cancer Research: Evidence

  2026-10-05

  This source-grounded overview examines Chloroquine Diphosphate as an autophagy and endosomal-pathway research tool, while separating supplier claims from peer-reviewed findings. It places the compound alongside a 2023 colorectal cancer study involving 3-bromopyruvate and cetuximab, explains possible conceptual applications in autophagy assay design and treatment-response research, and defines the evidence boundaries that prevent conclusions about chloroquine-specific cancer efficacy.

• AMPK–p62 Feedback Under Metabolic Stress

  2026-10-04

  Choi and colleagues identify a double-positive feedback loop linking AMPK and SQSTM1/p62 during metabolic stress, allowing coordinated activation of AMPK-dependent energy adaptation and NFE2L2/NRF2 antioxidant defense. The study connects lysosomal stress, KEAP1 degradation, TFEB/TFE3 regulation, and TAK1 signaling, while also defining important boundaries around the effects of lactic-acid-associated proton availability.

• WZ4003: NUAK1/2 Inhibitor Evidence Guide

  2026-10-03

  WZ4003 is a NUAK1/2 inhibitor with reported nanomolar biochemical potency and cellular evidence of NUAK pathway engagement. Peer-reviewed ex vivo brain-slice data link NUAK inhibition with lower tau Ser356 phosphorylation, while model-specific limitations prevent direct claims of therapeutic efficacy.

• TCF25 Links Lysosomal Acidification to Cell Death

  2026-10-01

  Ren et al. identify TCF25 as a nutrient-responsive regulator that strengthens V-ATPase-dependent lysosomal acidification during glucose starvation. The study shows that this response initially supports autophagy and ATP production but, during prolonged starvation, drives ferritinophagy, lysosomal membrane permeability, and lysosome-dependent cell death, with implications for hepatic ischemia-reperfusion injury.

• Triamcinolone: In Vitro Workflow and QC Guide

  2026-10-01

  Triamcinolone (B1859) provides a defined synthetic glucocorticoid agonist for controlled studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. This guide addresses solubility, stock preparation, storage, and assay controls; the research compound is not intended for diagnostic, therapeutic, or clinical use.

• CCK-8 Restores Morphine-Impaired Hippocampal LTP

  2026-09-30

  The reference study showed that intracerebroventricular CCK-8 restored hippocampal long-term potentiation weakened by acute morphine exposure in rats. Pharmacological blockade identified CCK2, rather than CCK1, receptors as the principal mediators, providing a mechanistic link between brain–gut peptide signaling, synaptic plasticity, and morphine-associated memory impairment.

• Oligo (dT) 25 Beads: mRNA Purification Guide

  2026-09-30

  Oligo (dT) 25 Beads provide a magnetic workflow for capturing polyadenylated eukaryotic mRNA from total RNA or animal and plant samples. They are not a universal RNA purification reagent and should not be used as the sole strategy for non-polyadenylated RNA, small RNA, or bacterial transcriptome recovery.

• Senolytic Targeting After Temozolomide in Glioblastoma

  2026-09-29

  The reference study shows that temozolomide-treated glioblastoma cells can persist in a senescent, apoptosis-resistant state supported by c-IAP2 and Bcl-2. Pharmacological inhibition with BV6 and venetoclax selectively increased death in these residual cells, providing a rationale for combining DNA-damaging therapy with senolytic strategies while highlighting important limits of cell-line evidence.

• Clathrin-Mediated Entry of Type III Grass Carp Reovirus

  2026-09-29

  Wang et al. used pharmacological inhibitors, transmission electron microscopy, and real-time quantitative PCR to define how genotype III grass carp reovirus enters CIK cells. Their results identify a dynamin-dependent, acidification-dependent clathrin pathway and show that amiloride does not inhibit viral entry under the tested conditions.

• FDA Drug Screen Identifies Lopinavir for MERS-CoV

  2026-09-28

  The study by de Wilde and colleagues screened 348 FDA-approved drugs and identified Lopinavir (ABT-378) among four compounds that inhibited MERS-CoV replication in cell culture at low-micromolar concentrations. Its main contribution was to demonstrate a practical drug-repurposing route for emerging coronavirus infections while also showing why cell-based activity must be separated from clinical efficacy and mechanism.

• Valemetostat and Dual EZH1/2 Inhibition in ATL

  2026-09-28

  This 2022 review explains why targeting both EZH1 and EZH2 may overcome compensatory epigenetic activity in adult T-cell leukemia/lymphoma (ATL), and summarizes the evidence behind valemetostat’s approval in Japan. Its main clinical signal was an overall response rate of 48% in a small, single-arm phase II study of relapsed or refractory ATL, supporting further evaluation while leaving comparative efficacy and longer-term outcomes unresolved.

• HOXC8 Suppresses CASP1-Driven Pyroptosis in Lung Cancer

  2026-09-27

  The study links HOXC8 overexpression in non-small cell lung cancer to transcriptional repression of CASP1, showing that HOXC8 depletion can trigger caspase-1- and gasdermin D-dependent pyroptotic death. Its mechanistic model implicates HDAC1/2 recruitment to the CASP1 promoter and suggests that this regulatory axis contributes to lung tumorigenesis.

• Mouse Tissue Lysis Kit K1038: Workflow and QC

  2026-09-26

  The Mouse Tissue Lysis Kit (K1038) prepares tissue lysate for direct PCR-based genotyping, avoiding a separate genomic DNA extraction and purification step. It is intended for research workflows, not diagnostic, clinical, or medical testing; consult the kit instructions for exact sample amounts and digestion conditions.

8681 records 4/579 page Previous Next 12345 下5页 Last page